Kapitalmarknadsdag 2023

IRLAB höll sin kapitalmarknadsdag den 17 oktober 2023.

Titta på live sändningen >

Presentationen (pdf) >

Program

Speaker biographies

Karl Kieburtz, MD, MHD, Professor in Neurology; President and co-founder Clintrex

Kieburtz is a Professor in the Department of Neurology at the University of Rochester School of Medicine and Dentistry and President and co-founder of Clintrex. He served as the inaugural Robert J Joynt Professor in Neurology, as the Director of the Clinical & Translational Science Institute and as the Senior Associate Dean for Clinical Research at the University of Rochester. He also was the Director of the Clinical Trial Coordination Center (CTCC) in the Department of Neurology for more than 20 years, Director of the Movement and Inherited Neurologic Disorders Unit, and was Co-Director of the Huntington and Parkinson Disease Centers of Excellence at the University of Rochester. Dr. Kieburtz is the past chair of the Parkinson Study Group Executive Committee, past member of the Huntington Study Group Executive Committee and Scientific Advisor to the Alzheimer Disease Cooperative Study (ADCS), and chaired the ADCS Data Safety Monitoring Board for over a decade, and continues to chair multiple DSMBs for AD clinical trials. He has served as an officer of the American Neurological Association, a member of the International Executive Committee of the Movement Disorder Society, and as Associate Editor of Neurology and of Movement Disorders. He has served as PI of many clinical trials sponsored by the NIH, the FDA and industry, and was Chair of the large NIH-sponsored NET-PD study. Dr. Kieburtz is an advisor to the Michael J Fox Foundation and directed the Clinical Core for the Fox Foundation sponsored Parkinson Progression Marker Initiative. He served as the Chair of the FDA Peripheral and Central Nervous System Advisory Committee, as the Chair of the VA’s Cooperative Studies Program Scientific Evaluation Committee and served as a consultant to NIH. He has served on numerous editorial and scientific advisory boards. He has lectured widely on therapeutic development for movement disorders and neurodegenerative diseases.

Gunnar Olsson, MD, PhD, CEO, IRLAB

Olsson is an Associate Professor at the Karolinska Institute, and honorary doctor of medicine at the Gothenburg University. Adjucnt professor at the Karolinska Institute 1998-2010. 35-years experience in life science industry. Served in leading positions in AstraZeneca for 25 years, whereof 10 years as head of the Therapy Areas Cardiovascular and Gastrointestinal in Global R&D. Been responsible for the development of seven global blockbusters/mega brands. Since 2013 served at board level and been consulting in bio-tech companies emanating from Swedish academic research. Olsson is also board member in IRLAB Therapeutics AB.

Joakim Tedroff, MD, CMO, IRLAB

Tedroff is a consultant neurologist specializing in neurodegenerative disorders. He is also an associate professor of neurology at the Department of Clinical Neuroscience at Karolinska Institutet. Joakim has more than 20 years of experience from the pharmaceutical industry with extensive experience conducting clinical research from Phase 1-3 clinical studies. He was co-founder of Carlsson Research and in 2013 he co-founded IRLAB. He previously held a position as CMO at A. Carlsson Research AB, and as scientific Vice President at NeuroSearch. He has been a director of Stockholm Brain Institute, XBrane Biopharma, Integrative Research Laboratories AB and served as chairman of Abera Bioscience. Joakim has also served as a consultant for a number of pharmaceutical companies in the neurology field including Allergan, Orion, Pfizer, Abbvie and Lundbeck as well as for venture capital firms in life science projects.

Peter Wallich, Commercial Director, IRLAB

Wallich has over 30 years’ experience in the pharmaceutical industry and has been working in senior commercial roles in AstraZeneca (VP Nexium and Losec) and Novartis as well as in R&D Product Development in AstraZeneca (Global Product Head Nexium).  Peter has a BSC (hon) degree and Masters of Commerce from Australia and has been working Global positions based in Sweden and Switzerland. He has worked across several therapeutic areas including Gastroenterology, Cardiology, Diabetes, Neurosciences and Oncology.

Nicholas Waters, PhD, EVP, Head of R&D, IRLAB

Waters worked as a Ph.D. student in Nobel Laureate Professor Arvid Carlsson’s research group at the Department of Pharmacology, Göteborg University (1987-1995). In 1996, Nicholas was awarded the Swedish Brain Foundation award. Between 1995 and 2000, he was managing research collaborations between the University and Pharma Industry partners. In 1998, he co-founded Carlsson Research. In the years 1998-2002, he served as member of the board of directors at Carlsson Research. In 2002, he was appointed Chief Scientific Officer at Carlsson Research and in 2006 he was appointed CEO. In 2006, Carlsson Research was sold to NeuroSearch and changed name to NeuroSearch Sweden. In 2010 he was appointed Executive Vice President, Research at NeuroSearch. Nicholas continued to serve as CEO of NeuroSearch Sweden through 2012. In 2013, Nicholas co-founded IRLAB. During the years 2007-2010 he served as board member of SwedenBIO, the Swedish Biotech industry association. Nicholas holds a Ph.D. in Pharmacology. Nicholas served as the CEO of IRLAB between 2016-2022 and in IRLAB Sweden between 2013-2022.